Health.Global

Why is Healthcare Global Enterprises Ltd falling/rising?

As of 09-Aug, Healthcare Global Enterprises Ltd's stock price has risen to 675.85, up 0.8%, driven by consistent performance, increased investor participation, and strong financial growth. The stock is trading above key moving averages and has outperformed benchmark indices, indicating robust fundamentals and positive market sentiment.

As of 09-Aug, Healthcare Global Enterprises Ltd is experiencing a rise in its stock price, currently at 675.85, reflecting an increase of 5.35 (0.8%). This upward movement can be attributed to several positive factors. The stock has shown consistent performance, gaining for the last three days with a total return of 1.57% during this period. Additionally, it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong bullish trend.<BR><BR>Investor participation has also increased, as evidenced by a significant rise in delivery volume, which was up by 36.93% compared to the 5-day average. This suggests growing confidence among investors. The company has reported healthy long-term growth, with operating profit and net profit increasing at annual rates of 195.08% and 193.02%, respectively. The positive financial results declared in the last two quarters further bolster investor sentiment.<BR><BR>Moreover, the stock has outperformed the benchmark indices, generating an 11.15% return over the past year, while the broader market has seen a decline. The high institutional holdings at 21.94% indicate that knowledgeable investors are backing the stock, which can enhance its stability and attractiveness.<BR><BR>Overall, these factors contribute to the rising stock price of Healthcare Global Enterprises Ltd, reflecting strong fundamentals and positive market sentiment.

Which are the latest news on Health.Global?

Should I buy, sell or hold Healthcare Global Enterprises Ltd?

When is the next results date for Healthcare Global Enterprises Ltd?

The next results date for Healthcare Global Enterprises Ltd is 06 August 2026.

The next results date for Healthcare Global Enterprises Ltd is on 06 August 2026.

What does Health.Global do?

HealthCare Global Enterprises Ltd operates in the hospital industry, focusing on oncology services. As of March 2026, it reported net sales of 652 Cr and a net profit of 2 Cr, with a market cap of INR 9,545 Cr.

Overview: <BR>Healthcare Global Enterprises Ltd operates in the hospital industry and is classified as a small-cap company.<BR><BR>History: <BR>The company was originally incorporated as Curie Centre of Oncology Private Limited in 1998. It underwent a name change to HealthCare Global Enterprises Private Limited in 2005 and was converted into a Public Limited Company in 2006, adopting its current name. The latest quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 652 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 2 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 9,545 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 164.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.90 <BR>Return on Equity: 4.38% <BR>Price to Book: 7.13 <BR><BR>Contact Details: <BR>Address: HCG Tower No 8 Kalinga Rao Rd, Sampangi Rama Nagar Bangalore Karnataka : 560027 <BR>Tel: 91-80-4660-7700 <BR>Email: sunumanuel@hcgoncology.com <BR>Website: http://www.hcgel.com

How big is Health.Global?

As of 10th June, Healthcare Global Enterprises Ltd has a market capitalization of 9,545.00 Cr, with recent net sales of 2,545.41 Cr and a net profit of 13.76 Cr. Shareholder's funds are 922.44 Cr, and total assets are valued at 3,518.24 Cr.

As of 10th June, Healthcare Global Enterprises Ltd has a market capitalization of 9,545.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 2,545.41 Cr and a Net Profit of 13.76 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 922.44 Cr and Total Assets valued at 3,518.24 Cr.

Who are in the management team of Health.Global?

The management team of Health.Global includes Basavalinga Ajaikumar Sadashivaiah (Chairman, Executive Director & CEO), Siddharth Patel (Non-Executive Director), Anjali Ajaikumar Rossi (Executive Director), and several independent and non-executive directors, along with Meghraj Arvindrao Gore (Whole Time Director & CEO) and Sunu Manuel (Company Secretary & Compliance Officer), collectively bringing diverse expertise to the company.

The management team of Health.Global includes the following key individuals:<BR><BR>1. **Basavalinga Ajaikumar Sadashivaiah** - Chairman, Executive Director & CEO<BR>2. **Siddharth Patel** - Non-Executive Director<BR>3. **Anjali Ajaikumar Rossi** - Executive Director<BR>4. **Geet Mathur** - Independent Non-Executive Director<BR>5. **Rajagopalan Raghavan** - Independent Non-Executive Director<BR>6. **Pradip M. Kanakia** - Independent Non-Executive Director<BR>7. **Meghraj Arvindrao Gore** - Whole Time Director & CEO<BR>8. **Amit Soni** - Non-Executive Director<BR>9. **Rajiv Maliwal** - Independent Non-Executive Director<BR>10. **Sunu Manuel** - Company Secretary & Compliance Officer<BR><BR>This team brings a diverse range of expertise and leadership to the company.

Who are the peers of the Health.Global?

Health.Global's peers include Global Health, Krishna Institute, Dr. Agarwal's Health, Rainbow Children, Jupiter Life Line, Yatharth Hospital, Jeena Sikho, Kovai Medical, and Artemis Medicare. Health.Global has average management risk and below average growth, with a 1-year return of 16.85%, lower than Yatharth Hospital's 57.94%.

Peers: The peers of Health.Global are Global Health, Krishna Institu., Dr Agarwal's Hea, Rainbow Child., Jupiter Life Lin, Yatharth Hospit., Jeena Sikho, Kovai Medical, and Artemis Medicare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Global Health, Krishna Institu., Jupiter Life Lin, and Kovai Medical, while Good management risk is found at Dr Agarwal's Hea, Rainbow Child., and Yatharth Hospit. Average management risk is present at Health.Global and Jeena Sikho, while Below Average management risk is noted for Yatharth Hospit. Growth is Excellent at Health.Global, Jeena Sikho, and Yatharth Hospit., while Good growth is seen at Dr Agarwal's Hea and Yatharth Hospit. Below Average growth is found at Global Health, Krishna Institu., Rainbow Child., Jupiter Life Lin, and Kovai Medical, and the rest. Capital Structure is Excellent at Global Health and Jupiter Life Lin, Good at Krishna Institu., Dr Agarwal's Hea, Rainbow Child., Kovai Medical, and Artemis Medicare, while Below Average is noted for Health.Global.<BR><BR>Return Snapshot: Yatharth Hospit. has the highest 1-year return at 57.94%, while Jeena Sikho has the lowest return with N/A, and Health.Global's 1-year return of 16.85% is lower than Yatharth Hospit. but higher than Jeena Sikho. Additionally, the six-month returns for Health.Global, Dr Agarwal's Hea, Jeena Sikho, Jupiter Life Lin, and Artemis Medicare are negative.

Are Healthcare Global Enterprises Ltd latest results good or bad?

Healthcare Global Enterprises Ltd's latest results are concerning, showing a 70.52% decline in net profit despite an 11.48% increase in net sales. The company's financial challenges, including high interest costs and low return on equity, overshadow its revenue growth.

Healthcare Global Enterprises Ltd's latest results present a mixed picture, leaning towards the negative side. In the fourth quarter of FY26, the company reported consolidated net profit of ₹2.17 crores, which is a significant decline of 70.52% year-on-year. This sharp drop in profitability raises concerns about the company's ability to convert its revenue growth into actual earnings.<BR><BR>On the positive side, net sales reached ₹652.33 crores, reflecting an 11.48% increase year-on-year, which indicates strong revenue generation capabilities. Additionally, the operating margin improved to 19.23%, suggesting better operational efficiency.<BR><BR>However, the stark contrast between rising revenues and plummeting profits highlights serious underlying issues. High interest costs and depreciation, along with a very low return on equity of 3.84%, indicate that the company is struggling to manage its capital effectively. Furthermore, the stock has underperformed compared to its peers in the hospital sector, which raises further concerns about its market position and valuation.<BR><BR>Overall, while there are some positive aspects in terms of revenue growth and operational margins, the significant decline in net profit and the company's financial challenges suggest that the latest results are more concerning than encouraging.

Is Health.Global technically bullish or bearish?

As of December 3, 2025, the trend is mildly bullish due to positive daily moving averages and Bollinger Bands, but caution is advised due to mixed signals from the MACD, KST, and monthly RSI.

As of 3 December 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating bullishness and the Bollinger Bands showing a mildly bullish signal on both weekly and monthly time frames. However, the MACD and KST on the weekly are mildly bearish, and the monthly RSI is bearish, suggesting some caution. Overall, the mixed signals indicate a mildly bullish outlook with underlying weaknesses that could affect momentum.

Is Health.Global overvalued or undervalued?

As of November 24, 2025, Health.Global is considered undervalued with an attractive valuation grade, despite having a high PE ratio of 286.73 and an EV to EBITDA ratio of 27.53, while outperforming the Sensex with a 53.86% return over the past year.

As of 24 November 2025, Health.Global's valuation grade has moved from fair to attractive, indicating a more favorable assessment of its market position. The company is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 286.73, an EV to EBITDA ratio of 27.53, and a ROCE of 7.64%. <BR><BR>In the peer comparison, Health.Global's PE ratio significantly exceeds that of Apollo Hospitals, which stands at 63.22, while its EV to EBITDA ratio is also higher than Apollo's 33.25. This suggests that Health.Global may be overvalued on a relative basis despite its attractive grade. Notably, the company's stock has outperformed the Sensex over the past year, returning 53.86% compared to the Sensex's 7.31%, reinforcing the notion of its strong market performance despite the high valuation ratios.

How has been the historical performance of Health.Global?

Health.Global has shown strong growth in net sales, reaching 2,222.85 Cr in March 2025, with operating profit increasing to 387.28 Cr and a margin of 17.46%. However, profit before tax declined to 56.19 Cr, and the company faces cash management challenges despite improved operating cash flow.

Answer:<BR>The historical performance of Health.Global shows a significant upward trend in net sales and operating profit over the past several years, culminating in a net sales figure of 2,222.85 Cr for the year ending March 2025, up from 1,912.12 Cr in March 2024 and 1,694.44 Cr in March 2023. The total operating income has also increased consistently, reaching 2,222.85 Cr in March 2025. Operating profit, excluding other income, rose to 387.28 Cr in March 2025 from 329.59 Cr in March 2024, reflecting a healthy operating profit margin of 17.46%. However, profit before tax decreased to 56.19 Cr in March 2025 from 67.33 Cr in March 2024, leading to a profit after tax of 48.06 Cr, slightly up from 40.93 Cr the previous year. <BR><BR>In terms of assets and liabilities, total assets increased to 3,518.24 Cr in March 2025 from 2,700.44 Cr in March 2024, while total liabilities also rose to 3,518.24 Cr, indicating a balanced growth. The company’s total debt increased to 1,002.23 Cr in March 2025 from 672.76 Cr in March 2024. Cash flow from operating activities improved to 317.00 Cr in March 2025, although the net cash outflow was recorded at -213.00 Cr, indicating challenges in cash management. Overall, Health.Global has shown growth in sales and operating profit, but faces pressures on profitability and cash flow management.<BR><BR>Breakdown:<BR>Health.Global has demonstrated a robust growth trajectory in net sales, which reached 2,222.85 Cr in March 2025, marking a significant increase from 1,912.12 Cr in March 2024 and 1,694.44 Cr in March 2023. The total operating income mirrored this growth, also hitting 2,222.85 Cr in March 2025. Operating profit, excluding other income, rose to 387.28 Cr, up from 329.59 Cr the previous year, resulting in an operating profit margin of 17.46%. Despite this positive trend, profit before tax saw a decline to 56.19 Cr in March 2025 from 67.33 Cr in March 2024, leading to a profit after tax of 48.06 Cr, which is an increase from 40.93 Cr in the prior year. <BR><BR>On the balance sheet, total assets surged to 3,518.24 Cr in March 2025, compared to 2,700.44 Cr in March 2024, while total liabilities matched this figure, indicating a balanced growth. The total debt increased to 1,002.23 Cr in March 2025 from 672.76 Cr in March 2024. Cash flow from operating activities improved to 317.00 Cr, yet the company faced a net cash outflow of -213.00 Cr, highlighting ongoing challenges in cash management despite the growth in sales and operating profit.

Who are the top shareholders of the Health.Global?

The top shareholders of Health.Global include Aceso Company Pte. Ltd. with 60.35%, followed by mutual funds at 9.19%, individual investors at 10.43%, and foreign institutional investors at 2.45%. The largest public shareholder is Tata India Pharma & Healthcare Fund, owning 3.42%.

The top shareholders of Health.Global include Aceso Company Pte. Ltd., which holds the largest stake at 60.35%. The promoters are the majority shareholders, with a pledged promoter holding of 4.995%. Additionally, mutual funds hold 9.19% of the shares across 9 schemes, while foreign institutional investors (FIIs) have a combined holding of 2.45% through 85 different entities. The highest public shareholder is Tata India Pharma & Healthcare Fund, which owns 3.42%. Individual investors collectively hold 10.43% of the company's shares.

Has Health.Global declared dividend?

No Dividend History Available